Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Supervisors info:
Μαρία Γαβριατοπούλου, Επίκουρη Καθηγήτρια Ιατρικής Σχολής ΕΚΠΑ
Φλώρα Ζαγουρή, Αναπληρώτρια Καθηγήτρια Ιατρικής Σχολής ΕΚΠΑ
Ευάγγελος Τέρπος, Καθηγητής Ιατρικής Σχολής ΕΚΠΑ
Original Title:
Clinical development of Ixazomib in plasma cell dyscrasias
Translated title:
Clinical development of Ixazomib in plasma cell dyscrasias
Summary:
Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in Multiple Myeloma.
The oral formulation of ixazomib makes it unique in the sense that it is an integral part of the only currently approved oral triplet for relapsed/refractory MM that incorporates both a PI and an immunomodulatory agent. The clinical efficacy, ease of administration, tolerability and synergy with other drug classes make ixazomib a valuable arsenal in the increasingly widening therapeutic armamentarium against MM
Main subject category:
Health Sciences
Keywords:
Oral anti-myeloma therapy, Small molecule proteasome inhibitor, Novel agent, Maintenance therapy, Quality of life
File:
File access is restricted only to the intranet of UoA.
MARIA BOURNAKI MASTER.pdf
1 MB
File access is restricted only to the intranet of UoA.
